Transcriptome-guided drug repurposing identifies selumetinib for an aggressive epithelial cancer
Authors:
- Sonja DorferSDSonja Dorfer
- Roland ZaunerRZRoland Zauner
- Christina Guttmann-GruberCGChristina Guttmann-Gruber
- Victoria ReichlVRVictoria Reichl
- Michael AblingerMAMichael Ablinger
- Julia I. HummelJHJulia I. Hummel
- Josefina Piñón HofbauerJHJosefina Piñón Hofbauer
- Ulrich KollerUKUlrich Koller
- Iris K. GratzIGIris K. Gratz
- Johann W. BauerJBJohann W. Bauer
- Verena WallyVWVerena Wally
Open Access
- 20 December 2025
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (7) , 1978-1988.e17
Abstract
No abstract availableKeywords
Funding Information
- Austrian Science Fund
- Dystrophic Epidermolysis Bullosa Research Association of America
- Paracelsus Medizinische Privatuniversität (2023-UP-007-Dorfer)
This publication has 63 references indexed in Scilit:
- Current progress in CRISPR-Cas systems for autoimmune diseases2024
- A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumorsInvestigational New Drugs, 2024
- Neue Lokal- und Systemtherapien bei Epidermolysis bullosahautnah, 2024
- Cancer immune escape: the role of antigen presentation machineryJournal of Cancer Research and Clinical Oncology, 2023
- Selumetinib: a selective MEK1 inhibitor for solid tumor treatmentClinical and Experimental Medicine, 2022
- Tumor and Systemic Immunomodulatory Effects of MEK InhibitionCurrent Oncology Reports, 2021
- Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis BullosaJAMA Dermatology, 2020
- Epithelial–mesenchymal transition in tumor metastasisMolecular Oncology, 2016
- Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapyCancer, 1990
- Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratomaCell, 1975